Back to search

Article

Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine plus Pioglitazone and All-Trans Retinoic Acid

2025-12-25

Abstract excerpt

The search for new therapeutic principles is essential for treating relapsed/refractory (r/r) acute myeloid leukemia (AML). Novel principles include genome-agnostic differentiation induction, controlling AML-triggering inflammation, potentiating the immune response and 'normalizing' AML metabolism. This review summarizes data from a phase I study (10 patients, pts) and three case reports (7pts) on the tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bae58561-e28d-522e-96c4-5fa480489e9d
DOI
10.20944/preprints202512.2313.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine plus Pioglitazone and All-Trans Retinoic AcidDOI 10.20944/preprints202512.2313.v1
Select a neighboring publication to make it the new centre.